<DOC>
	<DOCNO>NCT02210689</DOCNO>
	<brief_summary>A multi-center , double-blind , randomize , placebo control , parallel-group study , compare Clindamycin phosphate vaginal cream 2 % ( Watson Laboratories , Inc. ) Clindesse® ( Ther-Rx™ , Clindamyin Phosphate Vaginal Cream 2 % ) active treatment placebo control treatment bacterial vaginosis non-pregnant woman .</brief_summary>
	<brief_title>A Multi-center , Double-blind , Randomized Study , Comparing Clindamycin Phosphate Vaginal Cream 2 % ( Watson Laboratories , Inc. ) Clindesse® ( Ther-Rx™ , Clindamyin Phosphate Vaginal Cream 2 % ) Both Active Treatments Placebo Control Treatment Bacterial Vaginosis Non-pregnant Women</brief_title>
	<detailed_description>The study treatment period 1 day . Subject participation 22-30 day . Expected study duration 10 12 month . The study enroll 30 clinical site . Test Product : One single-dose , pre-filled disposable applicator deliver approximately 5 g cream contain approximately 100 mg clindamycin phosphate vaginal cream 2 % ( Watson Laboratories , Inc. ) Reference Product : One single-dose , pre-filled disposable applicator deliver approximately 5 g cream contain approximately 100 mg Clindesse® ( clindamycin phosphate vaginal cream 2 % ) ( Ther-Rx™ ) Placebo Control : One single-dose , pre-filled disposable applicator deliver approximately 5 g cream contain vehicle test product ( Watson Laboratories , Inc. ) Dose Mode A single applicator investigational product cream administer Administration intravaginally time day . The subject participation 22-30 day ( drug administration 1 day ) .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Vaginal Discharge</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<criteria>1 . Subjects must willing able understand comply requirement protocol , include attendance require study visit must provide write informed consent prior study related procedure perform . 2 . Healthy nonpregnant female age ≥ 18 year know medical condition , investigator 's opinion , may interfere study participation may interfere evaluation bacterial vaginosis . 3 . Female subject childbearing potential ( exclude woman surgically sterilize postmenopausal least 1 year ) , addition negative urine pregnancy test must willing use acceptable form birth control study day first dose administration Visit 2 Testofcure . For purpose study follow consider acceptable method birth control : Oral injectable contraceptive Contraceptive patch DepoProvera® ( stabilize least 3 month ) ; Implanon™ ( contraceptive implant ) , abstinence one abovelisted method birth control Subject become sexually active . A sterile sexual partner NOT consider adequate form birth control . Willing refrain sexual intercourse study day 17 48 hour prior Visit 2 Testofcure . 4 . Willing refrain use vaginal product ( e.g. , spermicide , tampon , douche , diaphragm , condom ) study product , study Days 17 , 48 hour prior first dose study product , 48 hour prior Visit 2 Testofcure . 5 . Diagnosis bacterial vaginosis , define presence follow : Clinical diagnosis bacterial vaginosis ( e.g. , thin , homogenous vaginal discharge associate minimal absent pruritus inflammation AND Saline wet mount vaginal discharge demonstrate proportion clue cell ≥ 20 % total epithelial cell AND Vaginal pH &gt; 4.5 , use pH paper measure 4.06.0 AND Positive `` whiff test '' addition drop 10 % KOH vaginal discharge ) Gram stain Nugent score ≥ 4 first day dosing ( study day 1 ) ( per Table 1 ) . Table 1 : Nugent Scoring System ( 010 ) Gramstained Vaginal Smears ( ) Score ( b ) Lactobacillus morphotypes Gardnerella Bacteroides spp . morphotypes Curved gramvariable rod 0 4+ 0 0 1 3+ 1+ 1+ 2+ 2 2+ 2+ 3+ 4+ 3 1+ 3+ 4 0 4+ Source : Nugent , R. P. , M. A. Krohn , S. L. Hillier . Reliability diagnose bacterial vaginosis improve standardized method Gram stain interpretation . J. Clin . Microbial . 1991 ; 29 : 297301 . Morphotypes score average number see per oil immersion field . Note less weight give curve gramvariable rod . Total score = lactobacilli + G. vaginalis Bacteroides spp/ + curve rod . 0 , No morphotypes present ; 1 , &lt; 1 morphotype present ; 2 , 1 4 morphotypes present ; 3 , 5 30 morphotypes present ; 4 , 30 morphotypes present . 1 . Female subject pregnant , nurse plan become pregnant study participation . 2 . Menstruating diagnosis bacterial vaginosis determine Baseline visit . 3 . Primary secondary immunodeficiency . 4 . Severe liver disease . 5 . History regional enteritis , ulcerative colitis , history `` antibioticassociated '' colitis . 6 . Evidence vulvovaginitis bacterial vaginosis . ( e.g. , candidiasis , Trichomonas vaginalis , Chlamydia trachomatis , Neisseria gonorrhoeae , Herpes simplex ) . 7 . Subjects visible sign HPV infection , i.e . visible wart . 8 . Subject another vaginal vulvar condition , would confound interpretation clinical response . 9 . Subject treatment study period cervical intraepithelial neoplasia ( CIN ) cervical carcinoma . 10 . History hypersensitivity clindamycin , lincomycin , component vaginal cream . 11 . Use within 2 week prior baseline 1 ) topical systemic antibiotic 2 ) topical systemic antifungal . 12 . Use spermicide , tampon , douche , diaphragm , condom within 48 hour baseline visit . 13 . Concurrent use systemic corticosteroid systemic antibiotic . 14 . Unwilling unable comply protocol requirement . 15 . Subjects participate investigational drug study ( i.e. , subject treat investigational drug ) within 30 day prior baseline exclude study participation . Subjects participate nontreatment study observational study registry study consider inclusion . 16 . Subjects previously enrol study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>